Post

New research · Infectious Disease
CVIR endovascular · 2d
Cohort studyCVIR endovascular · 2026

Percutaneous intrabiliary injection of gelatin sponge slurry for the management of acute hemobilia during biliary interventions: an alternative salvage technique.

Trieu Hai Pham, Nhat Minh Nguyen, Linh Chi Ho … Quyet Ta Nguyen
Read paper
Infectious DiseaseCohort study

Intrabiliary Gelfoam slurry was associated with immediate bleeding control in all hemobilia cases.

Percutaneous intrabiliary injection of gelatin sponge slurry for the management of acute hemobilia during biliary interventions: an alternative salvage technique.

Trieu Hai Pham et al. · CVIR endovascular · 2026
Purpose

To evaluate percutaneous intrabiliary injection of gelatin sponge (Gelfoam) slurry as a preliminary salvage technique for acute hemobilia during biliary interventions when angiographic embolization is unavailable.

Methods

We retrospectively reviewed eight patients with significant hemobilia during percutaneous biliary procedures between September 2024 and December 2025.

Results
immediate bleeding control was achieved in all patients
More results

One instance of recurrent bleeding at 10 days was successfully managed with a repeat injection.

Post-procedural infectious episodes (fever, leukocytosis) were observed in two patients (25%), requiring an upgrade in targeted antibiotic therapy.

“
Conclusion · 1 of 2

Preliminary experience suggests that intrabiliary Gelfoam slurry may represent a potential bridging or salvage maneuver for acute hemobilia in resource-constrained scenarios.

Conclusion · 2 of 2

However, because it relies on internal compression rather than definitive vascular repair, and carries potential risks of infectious exacerbation, it should be applied cautiously with strict follow-up and does not replace definitive transcatheter arterial embolization.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Randomized Trial
33.3%
this percentage of participants experienced fatigue, the most common side effect
Cohort Study
RR 0·60
Nirmatrelvir treatment led to a lower risk of long COVID at 3 months
Study
32-fold
removing the cfa gene made the bacteria much easier to kill with ampicillin